The benefit of abemaciclib in prognostic subgroups: An update to the pooled analysis of MONARCH 2 and 3

被引：1
|
作者：
O'Shaughnessy, Joyce [1 ]
Goetz, Matthew P. [2 ]
Sledge, George W. [3 ]
Martin, Miguel [4 ,5 ]
Lin, Yong [6 ]
Forrester, Tammy [6 ]
Smith, Ian C. [6 ]
Di Leo, Angelo [7 ]
Johnston, Stephen [8 ]
机构：
[1] Baylor Univ, Med Ctr, Texas Oncol, US Oncol, Dallas, TX USA
[2] Mayo Clin, Rochester, MN USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Geicam, Inst Invest Sanitaria Gregorio Maranon, Ciberonc, Madrid, Spain
[5] Univ Complutense, Madrid, Spain
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] Hosp Prato, Prato, Italy
[8] Royal Marsden NHS Fdn Trust, London, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT099
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT099
引用
收藏
页数：2
相关论文
共 50 条
  • [11] MONARCH 3: Abemaciclib as Initial Therapy for Patients with HR+/HER2-Advanced Breast Cancer
    Leo, A. D.
    Toi, M.
    Campone, M.
    Sohn, J. H.
    Shimon, S. P.
    Huober, J.
    Park, I. H.
    Tredan, O.
    Chen, S. -C.
    Manso, L.
    Freedman, O.
    Jaliffe, G. G.
    Forrester, T. D.
    Frenzel, M.
    Barriga, S.
    Smith, I. C.
    Bourayou, N.
    Goetz, M. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 5 - 5
  • [12] MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2-advanced breast cancer
    Di Leo, A.
    Toi, M.
    Campone, M.
    Sohn, J.
    Paluch-Shimon, S.
    Huober, J.
    Park, I. H.
    Tredan, O.
    Chen, S-C.
    Manso, L.
    Freedman, O.
    Jaliffe, G. G.
    Forrester, T.
    Frenzel, M.
    Barriga, S.
    Smith, I. C.
    Bourayou, N.
    Goetz, M. P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [13] Impact of abemaciclib on the time to subsequent chemotherapy and the time to second disease progression across the MONARCH 2 and 3 studies
    Tolaney, Sara M.
    Di Leo, Angelo
    Cussac, Antonio Llombart
    Dickler, Maura N.
    Campone, Mario
    Iwata, Hiroji
    Toi, Masakazu
    Kaufman, Peter A.
    Andre, Valerie A. M.
    Barriga, Susana
    Goetz, Matthew P.
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [14] Clinical implications of body mass index (BMI) and weight in metastatic breast cancer (BC) patients treated with abemaciclib and endocrine therapy: A pooled individual patient level data analysis of MONARCH 2 and MONARCH 3 trials (vol 31, pg s71, 2020)
    Franzoi, M. A.
    Ameye, L.
    Eiger, D.
    Piccart, M.
    Brandao, M. D. R. A.
    Ponde, N.
    Desmedt, C.
    Di Cosimo, S.
    Paesmans, M.
    Caparica, R.
    Kotecki, N.
    Lambertini, M.
    De Angelis, C.
    Awada, A. H.
    de Azambuja, E.
    ANNALS OF ONCOLOGY, 2020, 31 (10) : 1423 - 1423
  • [15] Efficacy of telcagepant in subgroups: pooled analysis of data from phase 3 studies
    Ho, T. W.
    Connor, K. M.
    Ho, A. P.
    Kost, J. T.
    Fan, X.
    Dodick, D. W.
    Silberstein, S. D.
    Lines, C. R.
    Assaid, C.
    JOURNAL OF HEADACHE AND PAIN, 2010, 11 : S40 - S41
  • [16] Efficacy of telcagepant in subgroups: pooled analysis of data from phase 3 studies
    Ho, T. W.
    Connor, K. M.
    Ho, A. P.
    Kost, J. T.
    Fan, X.
    Dodick, D. W.
    Silberstein, S. D.
    Lines, C. R.
    Assaid, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 245 - 245
  • [17] Efficacy of Telcagepant in Subgroups: Pooled Analysis of Data from Phase 3 Studies
    Ho, Tony W.
    Connor, Kathryn M.
    Ho, Andrew P.
    Kost, James T.
    Fan, Xiaoyin
    Dodick, David W.
    Silberstein, Stephen D.
    Lines, Christopher R.
    Assaid, Christopher
    NEUROLOGY, 2010, 74 (09) : A396 - A397
  • [18] Efficacy of Telcagepant in Subgroups: Pooled Analysis of Data from Phase 3 Studies
    Ho, T. W.
    Connor, K. M.
    Ho, A. P.
    Kost, J. T.
    Fan, X.
    Dodick, D. W.
    Silberstein, S. D.
    Lines, C. R.
    Assaid, C.
    HEADACHE, 2010, 50 : S16 - S16
  • [19] MONARCH 2: Interim analysis of overall survival in patients with poor prognostic factors
    Neven, Patrick
    Johnston, Stephen
    Toi, Masakazu
    Sohn, Joohyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga
    Okera, Meena
    Masuda, Norikazu
    Kaufman, Peter A.
    Koh, Han
    Grischke, Eva-Maria
    Conte, PierFranco
    Lu, Yi
    Haddad, Nadine
    Hurt, Karla
    Llombart-Cussac, Antonio
    Sledge, George W., Jr.
    CANCER RESEARCH, 2020, 80 (04)
  • [20] Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection A pooled analysis of 3,313 patients
    Maas, Monique
    Nelemans, Patty J.
    Valentini, Vincenzo
    Crane, Christopher H.
    Capirci, Carlo
    Roedel, Claus
    Nash, Garrett M.
    Kuo, Li-Jen
    Glynne-Jones, Rob
    Garcia-Aguilar, Julio
    Suarez, Javier
    Calvo, Felipe A.
    Pucciarelli, Salvatore
    Biondo, Sebastiano
    Theodoropoulos, George
    Lambregts, Doenja M. J.
    Beets-Tan, Regina G. H.
    Beets, Geerard L.
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (01) : 212 - 220
12345